| __timestamp | Intra-Cellular Therapies, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 21226345 | 18516000 |
| Thursday, January 1, 2015 | 87718074 | 34140000 |
| Friday, January 1, 2016 | 93831530 | 51872000 |
| Sunday, January 1, 2017 | 79419009 | 71772000 |
| Monday, January 1, 2018 | 132166913 | 97501000 |
| Tuesday, January 1, 2019 | 89124838 | 118590000 |
| Wednesday, January 1, 2020 | 65782137 | 169802000 |
| Friday, January 1, 2021 | 88845513 | 192507000 |
| Saturday, January 1, 2022 | 134715000 | 199563000 |
| Sunday, January 1, 2023 | 180142000 | 253598000 |
Unleashing insights
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Intra-Cellular Therapies, Inc. and Xencor, Inc. have demonstrated varying levels of investment in R&D, reflecting their strategic priorities.
From 2014 to 2023, Xencor, Inc. consistently outpaced Intra-Cellular Therapies, Inc. in R&D spending, with a notable 37% higher expenditure in 2023. This trend highlights Xencor's aggressive pursuit of innovation, particularly in the latter half of the decade. In contrast, Intra-Cellular Therapies, Inc. showed a steady increase in R&D investment, culminating in a 750% rise from 2014 to 2023.
These spending patterns underscore the dynamic nature of the biotech industry, where strategic R&D investments can drive future growth and competitive advantage.
Research and Development Investment: Zoetis Inc. vs Intra-Cellular Therapies, Inc.
Comparing Innovation Spending: Regeneron Pharmaceuticals, Inc. and Xencor, Inc.
Research and Development Expenses Breakdown: argenx SE vs Intra-Cellular Therapies, Inc.
Research and Development Investment: Genmab A/S vs Intra-Cellular Therapies, Inc.
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Opthea Limited
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Apellis Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs Amicus Therapeutics, Inc.
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends
Research and Development Expenses Breakdown: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
Comparing Innovation Spending: Amneal Pharmaceuticals, Inc. and Xencor, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Apellis Pharmaceuticals, Inc. and Xencor, Inc.
Ligand Pharmaceuticals Incorporated vs Xencor, Inc.: Strategic Focus on R&D Spending